Arctic Therapeutics clinical trials
Also known as ATx.
The registry lists 3 studies whose lead sponsor is Arctic Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 19, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 3studies on the registry
- 0open to participants now
- 2reach primary completion within a year
What it is testing
The drugs Arctic Therapeutics’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
2 of Arctic Therapeutics’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- 1AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
Add all 2 to your calendar (.ics) → With an account.
All 3 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 124
- 25
- 126
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Arctic Therapeutics.
- Arctic Therapeutics3 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 3 of 3.
- Safety and Efficacy of Topical AT-004 1% in Participants With Acne Vulgaris (AV)CompletedNCT07774364Phase 2
- Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)Active, not recruitingNCT07741526Phase 2
- Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)Active, not recruitingNCT07716865Phase 2